Table 6.
Major treatment and prognosis for CH and CH post CI [n (%)]
| Treatment and prognosis | Group A (n = 628) | Group B (n = 104) | P | |
|---|---|---|---|---|
| rTPA | 0.403 | |||
| No | 550 (87.6) | 88 (84.6) | ||
| Yes | 78 (12.4) | 16 (15.4) | ||
| Argatroban | 0.363 | |||
| No | 521 (83.0) | 90 (86.5) | ||
| Yes | 107 (17.0) | 14 (13.5) | ||
| LMWH | 0.059* | |||
| No | 606 (96.5) | 96 (92.3) | ||
| Yes | 22 (3.5) | 8 (7.7) | ||
| Warfarin | 0.536* | |||
| No | 624 (99.4) | 103 (99.0) | ||
| Yes | 4 (0.6) | 1 (1.0) | ||
| D-Anti-PLT | 0.852 | |||
| 0, no/single | 290 (46.2) | 47 (45.2) | ||
| 1, double | 338 (53.8) | 57 (54.8) | ||
| SILL | 0.744 | |||
| 0, no | 443 (70.5) | 75 (72.1) | ||
| 1, ILL | 185 (29.5) | 29 (27.9) | ||
rTPAvein thrombolysis with recombinant human tissue plasminogen activator. LMWH: Low-molecular-weight heparin. D-anti-PLT (platelets): Aspirin 100 mg or 300 mg + clopidogrel hydrogen sulfate 75 mg; SILL: Intensive lipid-lowering statins. *: Fisher’s exact test (2-sided)